Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications

Current Pharmaceutical Design

Volumn 14, Issue 25, 2008, Pages 2613-2618

  Yamagishi, Sho Ichi ^a   Ueda, Seiji ^a   Nakamura, Kazuo ^a   Matsui, Takanori ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ADMA; Diabetic vascular complications; Nitric oxide; Oxidative stress

Indexed keywords

DIMETHYLARGININASE; FARNESOID X RECEPTOR; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PIOGLITAZONE; TELMISARTAN;

AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DRUG MECHANISM; HUMAN; INSULIN RESISTANCE; NONHUMAN; NUCLEIC ACID METABOLISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW;

AMIDOHYDROLASES; ANIMALS; ARGININE; DIABETIC ANGIOPATHIES; HUMANS; NITRIC OXIDE SYNTHASE; RISK FACTORS;

EID: 57349128859     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786071326     Document Type: Review

References (86)

1. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-32.
2. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115: 1285-95.
3. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7.
4. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin Exp Nephrol 2007; 11: 115-21.
5. Ueda S, Yamagishi S, Kaida Y, Okuda S. Asymmetric dimethylarginine (ADMA) may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton) 2007; 12: 582-90.
6. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-9.
7. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007; 43: 511-8.
8. Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11: 2279-99.
9. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105.
10. Lee J, Sayegh J, Daniel J, Clarke S, Bedford MT. PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem 2005; 280: 32890-6.
11. Cook JR, Lee JH, Yang ZH, Krause CD, Herth N, Hoffmann R, et al. FBXO11/PRMT9, a new protein arginine methyltransferase, symmetrically dimethylates arginine residues. Biochem Biophys Res Commun 2006; 342: 472-81.
12. Rawal N, Rajpurohit R, Paik WK, Kim S. Purification and characterization of S-adenosylmethionine-protein-arginine N-methyltransferase from rat liver. Biochem J 1994; 300: 483-9.
13. Ghosh SK, Paik WK, Kim S. Purification and molecular identification of two protein methylase I from calf brain: myelin basic protein- and histone-specific enzyme. J Biol Chem 1988; 263: 19024-33.
14. Gary JD, Clarke S. RNA and protein interactions modulated by protein arginine methylation. Prog Nucl Acid Res Mol Biol 1998; 61: 65-131.
15. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
16. Tsikas D, Sandmann J, Savva A, Luessen P, Boger RH, Gutzki FM, et al. Assesssment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 742: 143-53.
17. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824-33.
18. Kielstein A, Tsikas D, Galloway GP, Mendelson JE. Asymmetric dimethylarginine (ADMA) - a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17: 55-9.
19. Teerlink T. HPLC analysis of ADMA and other methylated Larginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 21-9.
20. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851: 42-50.
21. Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269: H1522-7.
22. Segarra G, Medina P, Ballester RM, Lluch P, Aldasoro M, Vila JM, et al. Effects of some guanidino compounds on human cerebral arteries. Stroke 1999; 30: 2206-10.
23. Segarra G, Medina P, Vila JM, Chuan P, Domenech C, Torondel B, et al. Inhibition of nitric oxide activity by arginine analogs in human renal arteries. Am J Hypertens 2001; 14: 1142-8.
24. Gardiner SM, Kemp PA, Bennett T, Palmer RM, Moncada S. Regional and cardiac haemodynamic effects of NG, NG, dimethyl-Larginine and their reversibility by vasodilators in conscious rats. Br J Pharmacol 1993; 110: 1457-64.
25. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996; 28: 439-46.
26. Zoccali C, Kielstein JT. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens 2006; 15: 314-320.
27. Xiao S, Wagner L, Schmidt RJ, Baylis C. Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease. Kidney Int 2001; 59: 1466-72.
28. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-4.
29. Jeserich M, Munzel T, Just H, Drexler H. Reduced plasma L-arginine in hypercholesterolaemia. Lancet 1992; 339: 561.
30. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282: 879-87.
31. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of reninangiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24: 1682-8.
32. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1: 65-73.
33. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006; 17: 1128-34.
34. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52: 1593-1601.
35. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-92.
36. MacAllister RJ, Fickling SA, Whitley GS, Vallance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112: 43-8.
37. G- dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995; 117: 237-8.
38. G-dimethylarginine dimethylaminohydrolase. Eur J Biochem 1998; 258: 863-8.
39. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 1999; 343: 209-14.
40. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13: 198-203.
41. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-40.
42. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226-33.
43. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vasc Pharmacol 2006; 45: 268-276.
44. Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res 2008; 77: 19-29.
45. Kashyap SR, Roman LJ, Lamont J, Masters BS, Bajaj M, Suraamornkul S, et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab 2005; 90: 1100-1105.
46. Kurioka S, Koshimura K, Murakami Y, Nishiki M, Kato Y. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J 2000; 47: 77-81.
47. Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, Fukatsu A, Funami J, Ding QF, et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA 2006; 103: 17018-23.
48. Sorrenti V, Mazza F, Campisi A, Vanella L, Li Volti G, Di Giacomo C. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr Neurovasc Res 2006; 3: 49-54.
49. Chobanyan K, Thum T, Suchy MT, Zhu B, Mitschke A, Gutzki FM, et al. GC-MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 858: 32-41.
50. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M, et al. Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 2007; 50: 2562-71.
51. Yamagishi S, Matsui T, Nakamura K. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008; 15: 172-7.
52. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007; 194: e1-8.
53. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
54. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 63-79.
55. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 2: 430-6.
56. Bucala, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34.
57. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
58. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37: 586-600.
59. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13: 2832-7.
60. Lu CW, Xiong Y, He P. Dimethylarginine dimethylaminohydrolase- 2 overexpression improves impaired nitric oxide synthesis of endothelial cells induced by glycated protein. Nitric Oxide 2007; 16: 94-103.
61. Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljeflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism 2007; 56: 464-9.
62. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator- activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-9.
63. Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006; 70: 781-7.
64. Zsuga J, Török J, Magyar MT, Valikovics A, Gesztelyi R, Lenkei A, et al. Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. Metabolism 2007; 56: 394-9.
65. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008; 93: 82-90.
66. Ozgurtas T, Oktenli C, Dede M, Tapan S, Kenar L, Sanisoglu SY, et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008; (in press).
67. Konukoglu D, Firtina S, Serin O. The relationship between plasma asymmetrical dimethylarginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance. Metabolism 2008; 57: 110-5.
68. Eid HM, eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in population at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166: 279-84.
69. Krzyanowska W, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006; 189: 236-40.
70. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 2039-44.
71. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008; 31: 747-52.
72. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007; 30: 1834-9.
73. Yasuda S, Miyazaki S, Kanda M, Goto Y, Suzuki M, Harano Y, et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006; 27: 1159-65.
74. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843-6.
75. Kawata T, Daimon M, Hasegawa R, Teramoto K, Toyoda T, Sekine T, et al. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol 2008; (in press).
76. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circulation J 2002; 66: 811-5.
77. Chang JW, Lee EK, kim TH, Min WK, Chun S, Lee KU, et al. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a piloy study. Am J Nephrol 2007; 27: 70-4.
78. Yamagishi S, Ueda S, Okuda S. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes. Med Hypothese 2007; 69: 922-4.
79. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135-40.
80. Mittermayer F, Pleiner J, Krzyzanowska K, Wiesinger GF, Francesconi M, Wolzt M. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr 2005; 117: 816-20.
81. Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28: 255-62.
82. Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Täger M, Bode-Böger SM. Effect of telmisartan on nitric oxide - asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008; 51: 696-703.
83. Hu T, Chouinard M, Cox AL, Sipes P, Marcelo M, Ficorilli J, et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem 2006; 281: 39831-8.
84. Marshall SM. The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 2007; 13(26): 2713-20.
85. Yamagishi S, Matsui T, Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12(12): 1549-54.
86. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13(27): 2832-6.